Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Lilly Scraps Insulin Peglispro Amid Too Much Uncertainty

This article was originally published in Scrip

Executive Summary

Investors greeted Eli Lilly & Co.'s news with open arms the company was dumping its late-stage investigational types 1 and 2 diabetes treatment basal insulin peglispro (BIL) after deciding there was too much uncertainty about the product's future after issues arose concerning changes in liver fat in its Phase III IMAGINE trials.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register